Get the Stockscreener App
1.1369
11.02%
-0.1331
Sangamo Therapeutics Inc stock is traded at $1.1369, with a volume of 3.78M.
It is down -11.02% in the last 24 hours and down -17.52% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$1.27
Open:
$1.275
24h Volume:
3.78M
Relative Volume:
0.51
Market Cap:
$264.98M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-1.5159
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-8.13%
1M Performance:
-17.52%
6M Performance:
+31.87%
1Y Performance:
+133.13%
1-Day Range:
$1.13
$1.29
1-Week Range:
$1.13
$1.40
52-Week Range:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
1.1333 | 264.98M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.03 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.78 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.88 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo reports positive Fabry disease gene therapy results - MSN
Sangamo reports updated data for gene therapy candidate ST-920 - MSN
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace
Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com UK
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients - StockTitan
Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St
Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
HC Wainwright Has Bearish Forecast for SGMO FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
5 Best Stem Cell Companies to Invest In (February 2025) - Securities.io
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - The Eastern Progress Online
Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright - Defense World
Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts - Benzinga
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Truist Financial Has Lowered Expectations for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $5.17 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 - MarketBeat
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Q3 2018 First Look: Dancing With Data (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey
Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
State Street Corp Grows Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More - Zacks Investment Research
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):